NEW YORK (GenomeWeb) — Regulus Therapeutics announced this week that it has closed its previously announced public stock offering, raising $103.5 million through the transaction.
The company sold 6.1 million shares at $17 apiece. Roughly 4.8 million shares were sold by Regulus, with the remainder being sold by former parent firm Isis Pharmaceuticals.
Regulus expects its net proceeds from the offering to be about $76.1 million after expenses. The company will not receive any money from the sale of Isis' shares.